Clinical trials
Unresectable Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting unresectable pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 67 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04999761RecruitingPhase 1
Study testing new drug combinations for advanced cancers
This study tests new drug combinations for people with various advanced cancers that have progressed after standard treatment, or in some cases, as a first treatment. It aims to see if these combinations are safe and effective. The study is divided into groups based on cancer type and treatment history, so not everyone will qualify for every group.
AichiAges 18 years+ - NCT06219941RecruitingPhase 2
Studying AZD0901 for Claudin18.2-positive advanced solid tumors
This trial tests a new drug called AZD0901 for people with advanced solid tumors that have a specific protein on their surface. It aims to see if the drug can shrink or slow the growth of these tumors.
Orange, CaliforniaAges 18 years+ - NCT06937177RecruitingPhase 2
Testing mifomelatide to help maintain weight during chemo
This trial tests an investigational drug called mifomelatide (TCMCB07) to see if it can help people with newly diagnosed colorectal or pancreatic cancer maintain a healthy weight while receiving certain types of chemotherapy. You would give yourself a daily injection under the skin.
Tucson, ArizonaAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT05431270RecruitingPhase 1/Phase 2
Test drug that targets CD73, alone or with immunotherapy
This early-stage study tests mavrostobart (an anti-CD73 antibody) to see what dose is safe and whether it can help shrink tumors. It’s studied by itself and also with a PD-1 immune therapy or chemotherapy, depending on your cancer type and prior treatments.
Huntersville, North CarolinaAges 18 years+ - NCT06586515RecruitingPhase 1
Testing a new drug for cancers with KRAS G12D mutation
This trial tests a new pill (LY3962673) for people whose cancer has a specific DNA change called KRAS G12D. The drug aims to block the faulty protein that helps the cancer grow, and the study will look at safety and whether the tumor shrinks.
Duarte, CaliforniaAges 18 years+ - NCT06598007RecruitingPhase 1/Phase 2
Studying CT3001 for advanced solid tumors
This study tests an experimental drug called CT3001 for people with advanced solid tumors that haven't responded to other treatments. The goal is to see if it's safe and effective, and for some patients with colorectal cancer, it may be combined with standard chemotherapy.
Houston, TexasAges 18 years+ - NCT06835569RecruitingPhase 1
ALTA3263 for advanced KRAS-mutated solid tumors
This trial tests an experimental pill called ALTA3263 for adults with advanced solid tumors that have a specific KRAS mutation. It's for people who have already tried other treatments or can't take them.
Orlando, FloridaAges 18 years+ - NCT06882746RecruitingPhase 1
Testing different doses of BI 765049 for advanced colorectal, stomach, or pancreatic cancer
This study tests a new drug (BI 765049) at different doses for people with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The goal is to find a safe and effective dose.
Los Angeles, CaliforniaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07020221RecruitingPhase 1/Phase 2
Study of VS-7375 for KRAS G12D solid tumors
This trial tests a new oral drug called VS-7375 for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT07094204RecruitingPhase 1
A study of ASP5834 for adults with solid tumors and KRAS mutations
This trial is testing a new drug called ASP5834 for people with advanced solid tumors that have a specific change in the KRAS gene. The study will find the best dose and see if it helps shrink tumors.
Santa Monica, CaliforniaAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07458347RecruitingPhase 1
A new oral drug for KRAS-mutated advanced cancer
This trial tests a new oral drug, KST-6051, for people with advanced solid tumors (like lung, pancreatic, colon, or other cancers) that have a specific KRAS gene mutation. The goal is to find the best dose and see if it's safe.
Los Angeles, CaliforniaAges 18 years+ - NCT05424159Recruiting
Carbon ion radiation for locally advanced pancreatic cancer
This trial tests a type of radiation that uses carbon ions to treat pancreatic cancer that can’t be removed with surgery but has not spread to distant organs. It may help shrink or control the tumor while limiting radiation side effects to nearby organs.
ShanghaiAges 18–80 - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT07444541RecruitingPhase 1/Phase 2
Study of ANO31905 plus chemo for CLDN18.2-positive pancreatic cancer
This trial tests a new drug called ANO31905 added to standard chemotherapy for people with advanced pancreatic cancer that has a specific protein called CLDN18.2 on its cells. The study aims to see if the combination works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+ - NCT05000294RecruitingPhase 1/Phase 2
Atezolizumab plus tivozanib for hard-to-treat “cold” cancers
This early-stage study tests whether combining atezolizumab and tivozanib can shrink advanced, hard-to-treat cancers that do not strongly activate the immune system (“immunologically cold”). It is for people whose cancer has already been treated or has no good standard options.
Gainesville, FloridaAges 18–99
Hear when a new Unresectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for unresectable pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 67 recruiting unresectable pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a unresectable pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a unresectable pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.